Our Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS PF) Minimal Disease Activity (MDA), a tool developed at Johns Hopkins and validated within our PsA cohort, allows for exquisite description of […]
In 2015, Johns Hopkins scientists proved that scleroderma is often a casualty of war: it is the unfortunate consequence of the body’s battle to fight off cancer. We have since […]
Despite a very difficult year for all of us, remarkable things are being accomplished at Johns Hopkins Rheumatology, and I hope you will see that this issue of LEAP is […]
The vast majority of the patients who take statins don’t ever have to worry about the side effect of muscle symptoms. Even among those who do experience muscle damage, with […]
A prevalent belief among rheumatologists has been that an accurate diagnosis of Sjögren’s is not essential because of the lack of disease-modifying therapies. But a correct diagnosis is very important […]
This is an unusual time, and this year’s LEAP reflects it well: we start with Covid-19’s very sickest patients, and a Hopkins-wide team’s groundbreaking efforts to illuminate an unusual response in their immune system.
We end with a remarkable patient with a rare autoimmune disease: the legendary musician, Peter Frampton, who is not only raising awareness and research funding, but changing medical advice about how to preserve muscle function.
